» Articles » PMID: 33586614

The Role and Mechanism of MiR-557 in Inhibiting the Differentiation and Maturation of Megakaryocytes in Immune Thrombocytopenia

Overview
Journal RNA Biol
Specialty Molecular Biology
Date 2021 Feb 15
PMID 33586614
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Specific miRNA in immune thrombocytopenia (ITP) was screened to explore its intervention effects and mechanisms in ITP. MTT assay and CFSE staining were used to detect the effects of gradient concentrations of thrombopoietin (TPO) on cell proliferation. Expressions of differentially expressed miRNAs were analysed via qRT-PCR in TPO-induced megakaryocytes and ITP plasma. Effects of miR-557 on cell physiological functions were examined by MTT and flow cytometry. Expressions of miR-557, apoptosis-associated genes and Akt/ERK pathways were detected by qRT-PCR and Western blot as needed. Multinucleation of TPO-induced megakaryocytes was determined by megakaryocyte colonies. The toe skin and intestinal bleeding of the ITP rat model were observed and evaluated. Effects of miR-557 on the numbers of platelets, megakaryocytes, and peripheral blood platelets and the expressions of CD4 T cells, Treg cells, TGF-β, IL-6 and miR-557 in the ITP rats were detected by Giemsa staining, flow cytometry, ELISA and qRT-PCR. MiR-557 was identified as an specific miRNA associated with both ITP and TPO treatment. MiR-557 inhibitor enhanced the physiological functions of TPO-induced megakaryocytes, while miR-557 mimic had the opposite effect. At the molecular level, the expressions of miR-557, cleaved Caspase-3 and Bax were further silenced by inhibitor, on the contrary, the expressions of bcl-2, p-Akt and p-ERK were upregulated. Animal experiments showed that, miR-557 inhibitor increased the numbers of platelets and megakaryocytes, and improved the symptoms of ITP model rats. Our results indicated that miR-557 inhibitor improved ITP by regulating apoptosis-related genes and cellular immunity and activating the Akt/ERK pathway.

Citing Articles

The intersection of epigenetics and immune thrombocytopenia: new insights into disease mechanisms and treatments.

Zhou X, Shan N Mol Biol Rep. 2025; 52(1):257.

PMID: 39982580 DOI: 10.1007/s11033-025-10363-z.


Exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells regulate Th1/Th2 balance and alleviates immune thrombocytopenia in pregnancy.

Rong Y, Lu W, Huang X, Ji D, Tang D, Huang R Hum Cell. 2024; 38(1):31.

PMID: 39699695 DOI: 10.1007/s13577-024-01162-y.


A Comprehensive Review on Circulating cfRNA in Plasma: Implications for Disease Diagnosis and Beyond.

Zhong P, Bai L, Hong M, Ouyang J, Wang R, Zhang X Diagnostics (Basel). 2024; 14(10).

PMID: 38786343 PMC: 11119755. DOI: 10.3390/diagnostics14101045.


Pathogenesis of refractory ITP: Overview.

Cines D Br J Haematol. 2023; 203(1):10-16.

PMID: 37735546 PMC: 10539016. DOI: 10.1111/bjh.19083.


Scoping Review on Epigenetic Mechanisms in Primary Immune Thrombocytopenia.

Tan J, Ahmad Azahari A, Ali A, Ismail N Genes (Basel). 2023; 14(3).

PMID: 36980827 PMC: 10048672. DOI: 10.3390/genes14030555.


References
1.
Neunert C, Noroozi N, Norman G, Buchanan G, Goy J, Nazi I . Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2014; 13(3):457-64. PMC: 4991942. DOI: 10.1111/jth.12813. View

2.
cervinek L . Diagnosis and treatment of immune thrombocytopenia. Vnitr Lek. 2018; 64(5):526-529. View

3.
Visochek L, Cohen-Armon M . PARP1-Erk synergism in proliferating cells. Oncotarget. 2018; 9(49):29140-29145. PMC: 6044375. DOI: 10.18632/oncotarget.25633. View

4.
Sun R, Shan N . Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy. Cancer Cell Int. 2019; 19:59. PMC: 6419848. DOI: 10.1186/s12935-019-0779-0. View

5.
Sanchez V, Golyardi F, Mayaki D, Echavarria R, Harel S, Xia J . Negative regulation of angiogenesis by novel micro RNAs. Pharmacol Res. 2018; 139:173-181. DOI: 10.1016/j.phrs.2018.11.010. View